APO Research
Talk to an analyst

APO RESEARCH · REPORT

Musculoskeletal System Disorder Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Musculoskeletal System Disorder Drug Market Outlook and Growth Opportunities 2026

29 December 2025209 pages

Choose your research edition.

Industry ResearchMusculoskeletal System Disorder Drug Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Musculoskeletal System Disorder Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Musculoskeletal System Disorder Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Musculoskeletal System Disorder Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Musculoskeletal System Disorder Drug Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Musculoskeletal System Disorder Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Musculoskeletal System Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Musculoskeletal System Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Musculoskeletal System Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Musculoskeletal System Disorder Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Musculoskeletal System Disorder Drug market include Sanofi, Johnson & Johnson, Novartis, Eli Lilly, Pfizer, AbbVie, Torrent Pharmaceuticals, Nippon Shinyaku and Merck & Co, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Musculoskeletal System Disorder Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Musculoskeletal System Disorder Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Musculoskeletal System Disorder Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Musculoskeletal System Disorder Drug market.

Musculoskeletal System Disorder Drug Segment by Company

Sanofi

Johnson & Johnson

Novartis

Eli Lilly

Pfizer

AbbVie

Torrent Pharmaceuticals

Nippon Shinyaku

Merck & Co

GSK

Eisai

Cadila Healthcare

Bayer

Astellas Pharma

Asahi Kasei

Amgen

Abbott

Musculoskeletal System Disorder Drug Segment by Type

Bone Disorder

Joint Disorder

Muscle Disorder

Other

Musculoskeletal System Disorder Drug Segment by Application

Hospital & Clinic

Retail Pharmacy

Other

Musculoskeletal System Disorder Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Musculoskeletal System Disorder Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Musculoskeletal System Disorder Drug key companies, revenue, market share, and recent developments.

3. To split the Musculoskeletal System Disorder Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Musculoskeletal System Disorder Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Musculoskeletal System Disorder Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Musculoskeletal System Disorder Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Musculoskeletal System Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Musculoskeletal System Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Musculoskeletal System Disorder Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Musculoskeletal System Disorder Drug industry.

Chapter 3: Detailed analysis of Musculoskeletal System Disorder Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Musculoskeletal System Disorder Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Musculoskeletal System Disorder Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Musculoskeletal System Disorder Drug Industry Trends Table 2. Musculoskeletal System Disorder Drug Industry Drivers Table 3. Musculoskeletal System Disorder Drug Industry Opportunities and Challenges Table 4. Musculoskeletal System Disorder Drug Industry Restraints Table 5. Global Musculoskeletal System Disorder Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Musculoskeletal System Disorder Drug Revenue Share by Company (2021-2026) Table 7. Global Musculoskeletal System Disorder Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Musculoskeletal System Disorder Drug Key Company Manufacturing Base & Headquarters Table 9. Global Musculoskeletal System Disorder Drug Company, Product Type & Application Table 10. Global Musculoskeletal System Disorder Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Musculoskeletal System Disorder Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Bone Disorder Table 15. Significant Companies of Joint Disorder Table 16. Significant Companies of Muscle Disorder Table 17. Significant Companies of Other Table 18. Global Musculoskeletal System Disorder Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Musculoskeletal System Disorder Drug Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Musculoskeletal System Disorder Drug Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Musculoskeletal System Disorder Drug Sales Value Share by Type (2021-2026) Table 22. Global Musculoskeletal System Disorder Drug Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital & Clinic Table 24. Significant Companies of Retail Pharmacy Table 25. Significant Companies of Other Table 26. Global Musculoskeletal System Disorder Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Musculoskeletal System Disorder Drug Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Musculoskeletal System Disorder Drug Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Musculoskeletal System Disorder Drug Sales Value Share by Application (2021-2026) Table 30. Global Musculoskeletal System Disorder Drug Sales Value Share by Application (2027-2032) Table 31. Global Musculoskeletal System Disorder Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Musculoskeletal System Disorder Drug Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Musculoskeletal System Disorder Drug Sales Value Share by Region (2021-2026) Table 34. Global Musculoskeletal System Disorder Drug Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Musculoskeletal System Disorder Drug Sales Value Share by Region (2027-2032) Table 36. Global Musculoskeletal System Disorder Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Musculoskeletal System Disorder Drug Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Musculoskeletal System Disorder Drug Sales Value Market Share by Country (2021-2026) Table 39. Global Musculoskeletal System Disorder Drug Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Musculoskeletal System Disorder Drug Sales Value Market Share by Country (2027-2032) Table 41. Sanofi Company Information Table 42. Sanofi Business Overview Table 43. Sanofi Musculoskeletal System Disorder Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Sanofi Musculoskeletal System Disorder Drug Product Portfolio Table 45. Sanofi Recent Development Table 46. Johnson & Johnson Company Information Table 47. Johnson & Johnson Business Overview Table 48. Johnson & Johnson Musculoskeletal System Disorder Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Johnson & Johnson Musculoskeletal System Disorder Drug Product Portfolio Table 50. Johnson & Johnson Recent Development Table 51. Novartis Company Information Table 52. Novartis Business Overview Table 53. Novartis Musculoskeletal System Disorder Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Novartis Musculoskeletal System Disorder Drug Product Portfolio Table 55. Novartis Recent Development Table 56. Eli Lilly Company Information Table 57. Eli Lilly Business Overview Table 58. Eli Lilly Musculoskeletal System Disorder Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Eli Lilly Musculoskeletal System Disorder Drug Product Portfolio Table 60. Eli Lilly Recent Development Table 61. Pfizer Company Information Table 62. Pfizer Business Overview Table 63. Pfizer Musculoskeletal System Disorder Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Pfizer Musculoskeletal System Disorder Drug Product Portfolio Table 65. Pfizer Recent Development Table 66. AbbVie Company Information Table 67. AbbVie Business Overview Table 68. AbbVie Musculoskeletal System Disorder Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. AbbVie Musculoskeletal System Disorder Drug Product Portfolio Table 70. AbbVie Recent Development Table 71. Torrent Pharmaceuticals Company Information Table 72. Torrent Pharmaceuticals Business Overview Table 73. Torrent Pharmaceuticals Musculoskeletal System Disorder Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Torrent Pharmaceuticals Musculoskeletal System Disorder Drug Product Portfolio Table 75. Torrent Pharmaceuticals Recent Development Table 76. Nippon Shinyaku Company Information Table 77. Nippon Shinyaku Business Overview Table 78. Nippon Shinyaku Musculoskeletal System Disorder Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Nippon Shinyaku Musculoskeletal System Disorder Drug Product Portfolio Table 80. Nippon Shinyaku Recent Development Table 81. Merck & Co Company Information Table 82. Merck & Co Business Overview Table 83. Merck & Co Musculoskeletal System Disorder Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Merck & Co Musculoskeletal System Disorder Drug Product Portfolio Table 85. Merck & Co Recent Development Table 86. GSK Company Information Table 87. GSK Business Overview Table 88. GSK Musculoskeletal System Disorder Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. GSK Musculoskeletal System Disorder Drug Product Portfolio Table 90. GSK Recent Development Table 91. Eisai Company Information Table 92. Eisai Business Overview Table 93. Eisai Musculoskeletal System Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Eisai Musculoskeletal System Disorder Drug Product Portfolio Table 95. Eisai Recent Development Table 96. Cadila Healthcare Company Information Table 97. Cadila Healthcare Business Overview Table 98. Cadila Healthcare Musculoskeletal System Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Cadila Healthcare Musculoskeletal System Disorder Drug Product Portfolio Table 100. Cadila Healthcare Recent Development Table 101. Bayer Company Information Table 102. Bayer Business Overview Table 103. Bayer Musculoskeletal System Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Bayer Musculoskeletal System Disorder Drug Product Portfolio Table 105. Bayer Recent Development Table 106. Astellas Pharma Company Information Table 107. Astellas Pharma Business Overview Table 108. Astellas Pharma Musculoskeletal System Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Astellas Pharma Musculoskeletal System Disorder Drug Product Portfolio Table 110. Astellas Pharma Recent Development Table 111. Asahi Kasei Company Information Table 112. Asahi Kasei Business Overview Table 113. Asahi Kasei Musculoskeletal System Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Asahi Kasei Musculoskeletal System Disorder Drug Product Portfolio Table 115. Asahi Kasei Recent Development Table 116. Amgen Company Information Table 117. Amgen Business Overview Table 118. Amgen Musculoskeletal System Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Amgen Musculoskeletal System Disorder Drug Product Portfolio Table 120. Amgen Recent Development Table 121. Abbott Company Information Table 122. Abbott Business Overview Table 123. Abbott Musculoskeletal System Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Abbott Musculoskeletal System Disorder Drug Product Portfolio Table 125. Abbott Recent Development Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Musculoskeletal System Disorder Drug Product Image Figure 2. Global Musculoskeletal System Disorder Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Musculoskeletal System Disorder Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Musculoskeletal System Disorder Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Bone Disorder Image Figure 8. Joint Disorder Image Figure 9. Muscle Disorder Image Figure 10. Other Image Figure 11. Global Musculoskeletal System Disorder Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Musculoskeletal System Disorder Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Musculoskeletal System Disorder Drug Sales Value Share by Type (2021-2032) Figure 14. Hospital & Clinic Image Figure 15. Retail Pharmacy Image Figure 16. Other Image Figure 17. Global Musculoskeletal System Disorder Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Musculoskeletal System Disorder Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Musculoskeletal System Disorder Drug Sales Value Share by Application (2021-2032) Figure 20. Global Musculoskeletal System Disorder Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Musculoskeletal System Disorder Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Musculoskeletal System Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 23. North America Musculoskeletal System Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Musculoskeletal System Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Musculoskeletal System Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Musculoskeletal System Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Musculoskeletal System Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Musculoskeletal System Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 29. South America Musculoskeletal System Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Musculoskeletal System Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Musculoskeletal System Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Bone Disorder
  • Joint Disorder
  • Muscle Disorder
  • Other
Applications
  • Hospital & Clinic
  • Retail Pharmacy
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Eli Lilly
  • Pfizer
  • AbbVie
  • Torrent Pharmaceuticals
  • Nippon Shinyaku
  • Merck & Co
  • GSK
  • Eisai
  • Cadila Healthcare
  • Bayer
  • Astellas Pharma
  • Asahi Kasei
  • Amgen
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Musculoskeletal System Disorder Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Musculoskeletal System Disorder Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Musculoskeletal System Disorder Drug Market Dynamics
  1. 2.1 Musculoskeletal System Disorder Drug Industry Trends
  2. 2.2 Musculoskeletal System Disorder Drug Industry Drivers
  3. 2.3 Musculoskeletal System Disorder Drug Industry Opportunities and Challenges
  4. 2.4 Musculoskeletal System Disorder Drug Industry Restraints
3 Musculoskeletal System Disorder Drug Market by Company
  1. 3.1 Global Musculoskeletal System Disorder Drug Company Revenue Ranking in 2025
  2. 3.2 Global Musculoskeletal System Disorder Drug Revenue by Company (2021-2026)
  3. 3.3 Global Musculoskeletal System Disorder Drug Company Ranking (2024-2026)
  4. 3.4 Global Musculoskeletal System Disorder Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Musculoskeletal System Disorder Drug Company Product Type and Application
  6. 3.6 Global Musculoskeletal System Disorder Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Musculoskeletal System Disorder Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Musculoskeletal System Disorder Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Musculoskeletal System Disorder Drug Market by Type
  1. 4.1 Musculoskeletal System Disorder Drug Type Introduction
  2. 4.1.1 Bone Disorder
  3. 4.1.2 Joint Disorder
  4. 4.1.3 Muscle Disorder
  5. 4.1.4 Other
  6. 4.2 Global Musculoskeletal System Disorder Drug Sales Value by Type
  7. 4.2.1 Global Musculoskeletal System Disorder Drug Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Musculoskeletal System Disorder Drug Sales Value by Type (2021-2032)
  9. 4.2.3 Global Musculoskeletal System Disorder Drug Sales Value Share by Type (2021-2032)
5 Musculoskeletal System Disorder Drug Market by Application
  1. 5.1 Musculoskeletal System Disorder Drug Application Introduction
  2. 5.1.1 Hospital & Clinic
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Musculoskeletal System Disorder Drug Sales Value by Application
  6. 5.2.1 Global Musculoskeletal System Disorder Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Musculoskeletal System Disorder Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Musculoskeletal System Disorder Drug Sales Value Share by Application (2021-2032)
6 Musculoskeletal System Disorder Drug Regional Value Analysis
  1. 6.1 Global Musculoskeletal System Disorder Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Musculoskeletal System Disorder Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Musculoskeletal System Disorder Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Musculoskeletal System Disorder Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Musculoskeletal System Disorder Drug Sales Value (2021-2032)
  7. 6.3.2 North America Musculoskeletal System Disorder Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Musculoskeletal System Disorder Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Musculoskeletal System Disorder Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Musculoskeletal System Disorder Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Musculoskeletal System Disorder Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Musculoskeletal System Disorder Drug Sales Value (2021-2032)
  16. 6.6.2 South America Musculoskeletal System Disorder Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Musculoskeletal System Disorder Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Musculoskeletal System Disorder Drug Sales Value Share by Country, 2025 VS 2032
7 Musculoskeletal System Disorder Drug Country-level Value Analysis
  1. 7.1 Global Musculoskeletal System Disorder Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Musculoskeletal System Disorder Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Musculoskeletal System Disorder Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Musculoskeletal System Disorder Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Musculoskeletal System Disorder Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Musculoskeletal System Disorder Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Musculoskeletal System Disorder Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Musculoskeletal System Disorder Drug Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Musculoskeletal System Disorder Drug Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Musculoskeletal System Disorder Drug Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Musculoskeletal System Disorder Drug Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Musculoskeletal System Disorder Drug Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 AbbVie
  32. 8.6.1 AbbVie Company Information
  33. 8.6.2 AbbVie Business Overview
  34. 8.6.3 AbbVie Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie Musculoskeletal System Disorder Drug Product Portfolio
  36. 8.6.5 AbbVie Recent Developments
  37. 8.7 Torrent Pharmaceuticals
  38. 8.7.1 Torrent Pharmaceuticals Company Information
  39. 8.7.2 Torrent Pharmaceuticals Business Overview
  40. 8.7.3 Torrent Pharmaceuticals Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Torrent Pharmaceuticals Musculoskeletal System Disorder Drug Product Portfolio
  42. 8.7.5 Torrent Pharmaceuticals Recent Developments
  43. 8.8 Nippon Shinyaku
  44. 8.8.1 Nippon Shinyaku Company Information
  45. 8.8.2 Nippon Shinyaku Business Overview
  46. 8.8.3 Nippon Shinyaku Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nippon Shinyaku Musculoskeletal System Disorder Drug Product Portfolio
  48. 8.8.5 Nippon Shinyaku Recent Developments
  49. 8.9 Merck & Co
  50. 8.9.1 Merck & Co Company Information
  51. 8.9.2 Merck & Co Business Overview
  52. 8.9.3 Merck & Co Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck & Co Musculoskeletal System Disorder Drug Product Portfolio
  54. 8.9.5 Merck & Co Recent Developments
  55. 8.10 GSK
  56. 8.10.1 GSK Company Information
  57. 8.10.2 GSK Business Overview
  58. 8.10.3 GSK Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GSK Musculoskeletal System Disorder Drug Product Portfolio
  60. 8.10.5 GSK Recent Developments
  61. 8.11 Eisai
  62. 8.11.1 Eisai Company Information
  63. 8.11.2 Eisai Business Overview
  64. 8.11.3 Eisai Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Eisai Musculoskeletal System Disorder Drug Product Portfolio
  66. 8.11.5 Eisai Recent Developments
  67. 8.12 Cadila Healthcare
  68. 8.12.1 Cadila Healthcare Company Information
  69. 8.12.2 Cadila Healthcare Business Overview
  70. 8.12.3 Cadila Healthcare Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cadila Healthcare Musculoskeletal System Disorder Drug Product Portfolio
  72. 8.12.5 Cadila Healthcare Recent Developments
  73. 8.13 Bayer
  74. 8.13.1 Bayer Company Information
  75. 8.13.2 Bayer Business Overview
  76. 8.13.3 Bayer Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bayer Musculoskeletal System Disorder Drug Product Portfolio
  78. 8.13.5 Bayer Recent Developments
  79. 8.14 Astellas Pharma
  80. 8.14.1 Astellas Pharma Company Information
  81. 8.14.2 Astellas Pharma Business Overview
  82. 8.14.3 Astellas Pharma Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Astellas Pharma Musculoskeletal System Disorder Drug Product Portfolio
  84. 8.14.5 Astellas Pharma Recent Developments
  85. 8.15 Asahi Kasei
  86. 8.15.1 Asahi Kasei Company Information
  87. 8.15.2 Asahi Kasei Business Overview
  88. 8.15.3 Asahi Kasei Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Asahi Kasei Musculoskeletal System Disorder Drug Product Portfolio
  90. 8.15.5 Asahi Kasei Recent Developments
  91. 8.16 Amgen
  92. 8.16.1 Amgen Company Information
  93. 8.16.2 Amgen Business Overview
  94. 8.16.3 Amgen Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Amgen Musculoskeletal System Disorder Drug Product Portfolio
  96. 8.16.5 Amgen Recent Developments
  97. 8.17 Abbott
  98. 8.17.1 Abbott Company Information
  99. 8.17.2 Abbott Business Overview
  100. 8.17.3 Abbott Musculoskeletal System Disorder Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Abbott Musculoskeletal System Disorder Drug Product Portfolio
  102. 8.17.5 Abbott Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst